Login to Your Account

BDSI, Meda Partner On $90M+ Licensing Deal For Opioid Disc

By Donna Young

Thursday, September 6, 2007
BioDelivery Sciences International Inc. is set to receive $30 million in an up-front payment from Swedish specialty pharma Meda AB under a licensing agreement for BEMA Fentanyl, a dissolvable opioid disc product. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription